Vanda Pharmaceuticals | Beneficio Bruto En Ventas



Gross Profit On Sales Cambio Fecha
Acadia Pharmaceuticals USD 223.92M 13.87M 2025-03
Agios Pharmaceuticals USD 7.64M 1.83M 2025-03
Alnylam Pharmaceuticals USD 523.15M 32.8M 2025-03
Arrowhead Research -173085000 2.55M 2024-12
AstraZeneca USD 11.35B 819M 2025-03
Bristol-Myers Squibb USD 8.18B 947M 2025-03
Eli Lilly USD 10.5B 624.7M 2025-03
Halozyme Therapeutics USD 216.46M 39.49M 2025-03
Insmed USD 71.54M 6.75M 2025-03
J&J USD 14.6B 816M 2025-03
Ligand Pharmaceuticals USD 40.48M 509K 2025-03
Merck USD 12.77B 849M 2025-03
Moderna USD 17M 403M 2025-03
Novartis USD 10.24B 313M 2024-12
Pfizer USD 11.12B 987M 2025-03
PTC Therapeutics USD 196.89M 10.95M 2024-12
Sanofi EUR 7.72B 2.36B 2025-03
Takeda JPY 671.32B 55.93B 2025-03
Teva Pharmaceutical Industries USD 1.91B 206M 2025-03
Ultragenyx Pharmaceutical USD 110.63M 37.35M 2025-03
Veracyte USD 79.51M 754K 2025-03



Vanda Pharmaceuticals Beneficio Bruto En Ventas - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Jul 2025.